Evidence map›Paper›PMID 41904746›Full record

ArticleInternational journal of clinical oncology2026

Secondary primary tumors following iodine-125 low-dose-rate brachytherapy for localized prostate cancer.

Kojiro Niwa, Koji Iinuma, Masahiro Nakano, Masayuki Tomioka, Masaya Ito, Takayuki Mori, Kota Kawase, Tomoki Taniguchi, Yuki Tobisawa, Keita Nakane and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kojiro NiwaDepartment of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
Koji IinumaDepartment of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan. iinuma.koji.s0@f.gifu-u.ac.jp.ORCID http://orcid.org/0000-0002-0362-8624
Masahiro NakanoDepartment of Urology, Gifu Prefectural General Medical Center, 4-6-1 Noisiki, Gifu, Gifu, 500-8717, Japan.
Masayuki TomiokaDepartment of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
Masaya ItoDepartment of Radiology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
Takayuki MoriDepartment of Radiology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
Kota KawaseDepartment of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
Tomoki TaniguchiDepartment of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
Yuki TobisawaDepartment of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
Keita NakaneDepartment of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
Masayuki MatsuoDepartment of Radiology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.
Takuya KoieDepartment of Urology, Graduate School of Medicine, Gifu University, 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLow-dose-rate brachytherapy with iodine-125 (LDR-BT) is an established curative radiation treatment modality for localized prostate cancer (PCa). This study aimed to evaluate the long-term incidence of secondary primary tumors (SPTs) following LDR-BT in Japanese patients with localized PCa and identify predictive factors associated with SPTs. METHODS AND MATERIALS: We retrospectively reviewed the clinical records of 478 consecutive patients with localized PCa who underwent LDR-BT at the Gifu University Hospital. This study's primary endpoint was SPTs incidence, including bladder and rectal/anal cancers. The secondary endpoint was the identification of risk factors for LDR-BT that predicted SPTs development.

resultsAfter a median follow-up period of 105 months, SPTs developed in 13 patients (2.7%). Bladder cancer and rectal/anal canal cancer were observed in seven (1.5%) and six (1.3%) patients, respectively. Multivariate analysis showed that a biologically effective dose (BED) ≥ 197 Gy was associated with increased risk of SPTs (hazard ratio 4.145; 95% confidence interval 1.108-15.498; p = 0.035).

conclusionsThe incidence of SPTs following LDR-BT was relatively low. In multivariate analysis, BED ≥ 197 Gy may be associated with an increased risk of SPT occurrence. Adequate tumor control can be achieved through appropriate radiation dose administration; carefully planned long-term follow-up may be beneficial for SPTs early detection.

Indexed as

BrachytherapyIodine RadioisotopesNeoplasms, Radiation-InducedNeoplasms, Second PrimaryProstatic NeoplasmsAgedAged, 80 and overHumansIncidenceMaleMiddle AgedRadiotherapy DosageRetrospective StudiesRisk FactorsIodine-125Iodine RadioisotopesBiologically effective doseLate toxicityLow-dose-rate brachytherapyProstate cancerSecondary primary tumor

Identifiers

PMID41904746
PMCPMC13201275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.